Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant vesicular stomatitis virus-expressing interferon-beta
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Recombinant vesicular stomatitis virus-expressing interferon-beta (VSV-IFNβ) is an oncolytic virus engineered to express interferon-beta (IFNβ). This modification allows the virus to selectively replicate in and kill cancer cells while sparing normal cells. In tumor cells with defective IFN-β-mediated innate antiviral host defense mechanisms, VSV can replicate without interference, leading to cell lysis. However, in normal cells, the production of recombinant IFN-β activates an antiviral immune response that protects them against viral infection. VSV-IFNβ has demonstrated potent antitumor effects and promotes systemic antitumor immunity. The virus can be administered via intratumoral (IT) and intravenous (IV) routes.
- Other names
- VSV-IFNβ-NISVSV-IFNβ-TYRP1
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on recombinant vesicular stomatitis virus-expressing interferon-beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant vesicular stomatitis virus-expressing interferon-beta.